Intervention Review

You have free access to this content

Megestrol acetate for treatment of anorexia-cachexia syndrome

  1. Vicente Ruiz Garcia1,*,
  2. Eduardo López-Briz2,
  3. Rafael Carbonell Sanchis3,
  4. Jose Luis Gonzalvez Perales4,
  5. Sylvia Bort-Marti5

Editorial Group: Cochrane Pain, Palliative and Supportive Care Group

Published Online: 28 MAR 2013

Assessed as up-to-date: 31 AUG 2012

DOI: 10.1002/14651858.CD004310.pub3

How to Cite

Ruiz Garcia V, López-Briz E, Carbonell Sanchis R, Gonzalvez Perales JL, Bort-Marti S. Megestrol acetate for treatment of anorexia-cachexia syndrome. Cochrane Database of Systematic Reviews 2013, Issue 3. Art. No.: CD004310. DOI: 10.1002/14651858.CD004310.pub3.

Author Information

  1. 1

    Hospital Universitari i Politècnic La Fe, Unidad de Hospitalización a Domicilio & CASP Spain, Valencia, Valencia, Spain

  2. 2

    Hospital Universitario y Politécnico La Fe, Department of Pharmacy & CASP Spain, Valencia, Valencia, Spain

  3. 3

    Hospital de Sagunt, Servicio de Otorrinolaringologia, Sagunt, Valencia, Spain

  4. 4

    National Health Service, Algemesi, Valencia, Spain

  5. 5

    University of Valencia, Intellectual Property Department, Valencia, Spain

*Vicente Ruiz Garcia, Unidad de Hospitalización a Domicilio & CASP Spain, Hospital Universitari i Politècnic La Fe, Bulevar Sur s/n, Valencia, Valencia, 46026, Spain.

Publication History

  1. Publication Status: New search for studies and content updated (conclusions changed)
  2. Published Online: 28 MAR 2013


Cited in:


This article has been cited by:

  1. 1
    José M Garcia, Ralph V Boccia, Charles D Graham, Ying Yan, Elizabeth Manning Duus, Suzan Allen, John Friend, Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomised, placebo-controlled, double-blind trials, The Lancet Oncology, 2015, 16, 1, 108


  2. 2
    Amjad Husain, Nina Hu, Peter M. Sadow, Carmelo Nucera, Expression of angiogenic switch, cachexia and inflammation factors at the crossroad in undifferentiated thyroid carcinoma with BRAFV600E, Cancer Letters, 2015,


  3. 3
    Maria Carolina S Mendes, Gustavo D Pimentel, Felipe O Costa, José B C Carvalheira, Molecular and neuroendocrine mechanisms of cancer cachexia, Journal of Endocrinology, 2015, 226, 3, R29


  4. 4
    John E. Morley, Stephan von Haehling, Stefan D. Anker, Are we closer to having drugs to treat muscle wasting disease?, Journal of Cachexia, Sarcopenia and Muscle, 2014, 5, 2
  5. 5
    Joanne Reid, David Scott, Olinda Santin, Chris R. Cardwell, Michael Donnelly, W. George Kernohan, Peter Dominic O'Halloran, Joan Regan, Sam Porter, Evaluation of a Psychoeducational intervention for patients with Advanced Cancer who have Cachexia and their lay Carers (EPACaCC): study protocol, Journal of Advanced Nursing, 2014, 70, 5
  6. 6
    Christopher J. Wong, Involuntary Weight Loss, Medical Clinics of North America, 2014, 98, 3, 625


  7. 7
    Naoki Fujitsuka, Yasuhito Uezono, Rikkunshito, a ghrelin potentiator, ameliorates anorexia–cachexia syndrome, Frontiers in Pharmacology, 2014, 5,


  8. 8
    B. Reeves, S.A. Bernard, Pathobiology of Human Disease, 2014,


  9. 9
    Orla Hynes, Saira Chowdhury, Oesophageal cancer and nutrition,